Abemaciclib was recently licensed by the FDA as the first and only CDK4/6 inhibitor for use in HR+/HER2 node-positive early breast cancer patients with a Ki-67 score of less than 20% and a high risk of recurrence [62]. The gene discussed is CDK4; the disease is breast cancer.